JO3099B1 - طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد - Google Patents

طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد

Info

Publication number
JO3099B1
JO3099B1 JOP/2007/0221A JOP20070221A JO3099B1 JO 3099 B1 JO3099 B1 JO 3099B1 JO P20070221 A JOP20070221 A JO P20070221A JO 3099 B1 JO3099 B1 JO 3099B1
Authority
JO
Jordan
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
JOP/2007/0221A
Other languages
English (en)
Inventor
S Bajwa Joginder
Slade Joel
John Parker David
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3099(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3099B1 publication Critical patent/JO3099B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

تحضير املاح N- هيدروكسي -3- [4-[[[2-(2-مثيل-H 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-E2-2-بروبان اميد.بطرق مختلفة ومتنوعة.
JOP/2007/0221A 2006-06-12 2007-06-12 طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد JO3099B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452906P 2006-06-12 2006-06-12
US85325906P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
JO3099B1 true JO3099B1 (ar) 2017-03-15

Family

ID=38832680

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0221A JO3099B1 (ar) 2006-06-12 2007-06-12 طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد

Country Status (24)

Country Link
US (1) US7989639B2 (ar)
EP (1) EP2032532B8 (ar)
JP (1) JP2009540007A (ar)
KR (1) KR20090026282A (ar)
AR (1) AR061295A1 (ar)
AU (1) AU2007257882B2 (ar)
BR (1) BRPI0713653A2 (ar)
CA (1) CA2654230C (ar)
CL (1) CL2007001690A1 (ar)
EC (1) ECSP088957A (ar)
GT (1) GT200800281A (ar)
HK (1) HK1126495A1 (ar)
IL (1) IL195344A (ar)
JO (1) JO3099B1 (ar)
MA (1) MA30564B1 (ar)
MX (1) MX2008015899A (ar)
MY (1) MY147013A (ar)
NO (1) NO20090136L (ar)
NZ (1) NZ572744A (ar)
PE (1) PE20080365A1 (ar)
RU (1) RU2008151724A (ar)
TN (1) TNSN08508A1 (ar)
TW (1) TWI385142B (ar)
WO (1) WO2007146717A2 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007257962B2 (en) * 2006-06-12 2011-06-23 Secura Bio Inc. Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
CN102167678B (zh) * 2006-06-12 2013-08-28 诺瓦提斯公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺及其原料的制备方法
CN101678109A (zh) * 2007-01-10 2010-03-24 诺瓦提斯公司 脱乙酰酶抑制剂的制剂
WO2009119785A1 (ja) * 2008-03-28 2009-10-01 浜理薬品工業株式会社 エチニルチミジン化合物の精製方法
MX364930B (es) * 2013-12-02 2019-05-14 Suven Life Sciences Ltd Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado.
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat
WO2018092151A1 (en) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Amorphous panobinostat and its lactate salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20230416255A1 (en) * 2022-06-27 2023-12-28 Abion Inc. Mesylate salts of triazolopyrazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH342565A (de) 1954-04-14 1959-11-30 Thomae Gmbh Dr K Verfahren zur Herstellung von basischen Äthern endocyclisch substituierter Carbinole oder ihren nicht quaternären Salzen
GB891413A (en) 1958-10-06 1962-03-14 Smith Kline French Lab Tris-(dialkylaminoalkyl) phosphates and a method for their preparation
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
BR0213932A (pt) 2001-11-06 2004-08-31 Novartis Ag Combinação do inibidor da ciclooxigenase-2/inibidor da desacetilase histona
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
WO2005105740A2 (en) * 2004-04-26 2005-11-10 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod and tegaserod maleate
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts

Also Published As

Publication number Publication date
EP2032532B1 (en) 2015-04-22
TWI385142B (zh) 2013-02-11
IL195344A (en) 2014-11-30
CA2654230C (en) 2012-09-11
EP2032532A2 (en) 2009-03-11
TW200808692A (en) 2008-02-16
JP2009540007A (ja) 2009-11-19
AU2007257882A1 (en) 2007-12-21
KR20090026282A (ko) 2009-03-12
EP2032532B8 (en) 2015-07-01
IL195344A0 (en) 2009-08-03
RU2008151724A (ru) 2010-07-20
ECSP088957A (es) 2009-01-30
TNSN08508A1 (en) 2010-04-14
CL2007001690A1 (es) 2008-05-16
AU2007257882B2 (en) 2011-09-08
MY147013A (en) 2012-10-15
NO20090136L (no) 2009-03-06
BRPI0713653A2 (pt) 2012-10-23
MX2008015899A (es) 2009-04-01
AR061295A1 (es) 2008-08-20
US20090187029A1 (en) 2009-07-23
WO2007146717A2 (en) 2007-12-21
WO2007146717A3 (en) 2008-03-27
CA2654230A1 (en) 2007-12-21
GT200800281A (es) 2009-03-18
PE20080365A1 (es) 2008-05-07
US7989639B2 (en) 2011-08-02
MA30564B1 (fr) 2009-07-01
HK1126495A1 (en) 2009-09-04
NZ572744A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
MY149337A (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
JO3138B1 (ar) املاح n- هيدروكسي -3- [4-[[[2-(2-مثيل-h1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e2-2-بروبيناميد
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
TNSN08507A1 (en) Process for making n-hydroxy -3- [4-[[[2-(2-metyl -1h- indol -3- yl) ethyl] amino] methyl]phenyl] -2e -2- propenamide and starting materials therefor
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.